))	Europäisches Patentamt European Patent Office Office européen des brevets			80298 MU GERMAN Tel: +49 8	1
		Application No.: Patent No.:	08 732 818.3 EP-B-2 203 462	Direct decision □ yes X n	-
	Interlocutory decision in opposition proceedings (Art. 101(3)(a) and 106(2) EPC) The Opposition Division - at the oral proceedings dated 05.10.2016 - has decided: Account being taken of the amendments made by the patent proprietor during the opposition proceedings, the patent EP-B-2 203 462 and the invention to which it relates are found to meet the requirements of the Convention.				
	The currently valid documents are:				
	Auxiliary Request 1 Description, Pages 2-46 of the patent specification Description, Paragraphs				
	52		mendments filed during Oral Proceed	lings on	05-10-2016
	Claims, Nur 1, 2	nbers received on	03-08-2016 with letter of		03-08-2016
	The Grounds for the decision (Form 2916) are enclosed.				
	24/16/2 Date	1.C. Let Examine	Sotter 2nd Examiner Hartinger, Stefan	Legally qualified m Schauwecker, Ma	nember rko


EPO Form 2339 (Sheet 1) 12.07TRI




Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

Facts and Submissions

- 1 The contested patent has the patent number EP2203462 and is based upon the application number 08732818 with the title "NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS". The patent proprietor is Gilead Pharmasset LLC. The patent has 3 priority dates namely: 30.03.2007; 24.10.2007 and 21.03.2008.
- 2 Claim 1 of the patent in suit is directed to the following racemate




Claims 2-3 are directed to the enantiomers of this compound and have the following formulae:



EPO Form 2916 01.91TRI

R

Sheet



Claims 4-6 relate to compositions corresponding to claims 1-3 respectively.

- 3 A total of ten oppositions have been filed by the following opponents:
- 3.1 Médecins du Monde (Opponent 1) on 10.02.2015;
- 3.2 Mr H. H. Fleischer (Opponent 2) on 19.02.2015;
- 3.3 Ellis IP Ltd. (Opponent 3) on 19.02.2015;
- 3.4 Pharmaceutical Works Polpharma S.A. (Opponent 4) on 20.02.2015;
- 3.5 Generics [UK] Ltd (Opponent 5) on 20.02.2015;
- 3.6 Teva Pharmaceutical Industries Ltd; (Opponent 6) on 20.02.2015;
- 3.7 Intellectual Property Services (IPS) (Opponent 07) on 23.02.2015;
- 3.8 Stada Arzneimittel AG (Opponent 8) on 23.02.2015;
- 3.9 ZBM Patents S.L. (Opponent 9) on 23.02.2015;
- 3.10 Actavis Group PTC ehf (Opponent 10) on 23.02.2015
- 4 The following documents have been cited:
 - A1 assignment of D1
 - A2 assignment of D2
 - A3 assignment of D3
 - D1 US prov. appl. 60/909315 = 1st priority document of contested patent

EPO Form 2916 01.91TRI

Sheet

Feuille

- D2 US prov. appl. 60/982309 = 2nd priority document of contested patent
- D3 US prov. appl. 12/053015 = 3rd priority document of contested patent
- D4 WO2005/012327

D5 Thesis entitled "Design, Synthesis and Biological Evaluation of Novel Nucleotide Prodrugs as Potential Anti-Hepatitis C Virus Agents" submitted by Plinio Perrone

- D6 Ma et al 2007, J. Biol. Chem. 282: pp29812-29820
- D7 Perrone et al 2007 J. Med. Chem. 50, pp1840-1849

D7a Extract from website of J. Med. Chem. to confirm publication date of document D7

D8 Poster presented at the 14th International Symposium on Hepatitis C Virus and Related Viruses which was held in Glasgow (Scotland) on 9-13 September 2007

- D9 Murakami et al 2008 Antimicrob. Agents Chemother. 52:458-464
- D10 Clark et al 2005, J. Med. Chem. 48, pp5504-5508
- D11 Zemlicka 2002 Biochemica Acta 1587:276-286
- D12 WO2005/003147
- D13 WO2008/121634 application document of contested patent
- D14 Lehsten et al, Org. Proces Res. Dev. 2002, 6, 819-822
- D15 WO2011/123645
- D16 Cahard et al, Mini-Reviews in Medicinal Chemistry, 2004, 4, pp:371-381

D17 Jones et al., Minireview: Nucleotide Prodrugs. Antiviral Research 27 (1995), pp. 1-17

- D18 Lee et al, Antimicrobial Agents and Chemotherapy 2005. pp 1898-1906
- D19 WO 02/08241
- D20 McGuigan et al, J. Med. Chem, 2006, 49, pp 21 5-7226
- D21 Sofia et al. J, Med. Chem, 2010, 53, pp7202-7218

D22 Abstract 100 "Design, synthesis, and Biological evaluation of Novel Nucleoside PPAs as Potential Anti-HCV Agents' presented at the l4th international Conference on Antiviral Research May 7-11, 2006

D23 W02004/002999

EPO Form 2916 01.91TRI

RM

DOCKE

Sheet

Feuille

- D24 W02006/121820
- D25 W02006/012078
- D26 WO2006/065335
- D27 Gunic et al Bioorg & Med Chem. Letts 17(9) pp2456-2458 14.02.2007
- D28 US6475985
- D29 WO03/000713
- D30 WO2007/020193
- D31 US2006/0241064
- D32 WO2007/095269

D33 Ma et al "Characterization of the Intracellular metabolism of 3-D-2'deoxy-2'-fluoro-2'-C-methylcytidine. ... " Antiviral Research 2007 74 A36 Abstract 23

D34 Evidence as to the priority date of D33 and D35

D35 McGuigan et al "Sub Micromolar Inhibitors of HCV Generated from Inactive Nucleosides by Application of ProTide Technology" Antiviral Research 2007 74 A36 Abstract 24

- D36 McGuigan et al FEBS Letter (1994) 11-14
- D37 McGuigan et al, J. Med. Chem. 2005, pp3504-3515
- D38 Klumpp et al, J. Biol. Chem., 2006, vol. 281, pp3793-3799
- D40 US12/053015
- D42 Declaration of Dr Michael Sofia
- D43 Declaration of Dr Valentino Stella
- D44 Declaration of Professor John R. Thomas
- D45 Declaration of Dr Adrian Ray
- D45A Second Declaration of Dr Adrian Ray
- D46 Declaration of Dr Phillip Furman
- D47 Declaration of Dr William Delaney

D48A Email exchange dated 14 May 2015 regarding publication date

of D14

D48B Email exchange dated 12 November 201 5 regarding the period

EPO Form 2916 01.91TRI

DOCKE.

ARM

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.